To investigate the role of FZD6 in prostate cancer progression, we used 2 shRNAs to knock down FZD6 in 3 representative human prostate cancer cell lines that highly express FZD6: the androgen receptor (AR) negative DU145, androgen-independent but AR-expressing C4-2B and LN95. This evidence concerns the gene FZD6 and prostate carcinoma.